Biotech Values

[bellweather1]

TGTX—…continuation of stated plans for pivotal combo trials in 2H 2014.

To a limited degree(check at time 23:30 of presentation;slide 24):

TGTX will determine which combos to do in Ph3 depending on results of 1H 2014 studies:

1)PH2 of Anti CD20(1101)+ Ibrutinib in CLL & MCL

2)Ph2 of Anti CD20(1101)+ PIK3delta(TGR-1202) in various B-cell Malignancies.

Sounds like he assumes they will do at least one Ibrutinib combo, and very likely their own wholly internal combo(with particular B-cell malignancies treated dependent on Ph2 results).